Juno Therapeutics priced 11 million shares at $24 on the Nasdaq market, above the range of $21 to $23. The initial offer was 9.3 million shares at $15 to $18, before increasing its range on Tuesday. CEO Hans Bishop tells TheStreet's Jill Malandrino Juno is focused on the better treatment of patients with cancer. Juno's approach is to reprogram the patient's immune system so it can recognize cancer and kill it. In 2015, Bishop says there are 10 different cell products moving into the clinic which will boost the pipeline and Juno is also looking to build its own manufacturing facility. Proceeds from the capital raised will go to further R&D and talent investment, as well supporting the manufacturing development.